ABSI

Absci Corp is a clinical-stage biopharmaceutical company developing antibody therapeutics using its AI-native Origin-1 generative design platform combined with lab-in-the-loop validation, focusing on underexplored mechanisms in areas with high unmet need. The company's lead program, ABS-201, is an anti-prolactin receptor antibody with extended half-life being evaluated in Phase 1/2a for androgenetic alopecia and planned for Phase 2 development in endometriosis, both indications lacking durable, disease-modifying approved therapies. Absci has advanced its first two programs from AI design to IND in approximately two years at roughly $15 million per program, significantly faster and more cost-efficient than industry averages.

Pipeline

Catalyst Calendar